American Society of Hirudotherapy

Direct oral thrombin inhibitor, "dabigatran"

Review published in Nihon rinsho. Japanese journal of clinical medicine (2013)

Last Updated: November 1, 2026ASH Editorial · based on the books
Research article — evidence review: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Article reference: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
Evidence: Narrative reviewDrug DevelopmentYasaka · Nihon rinsho. Japanese journal of clinical medicine, 2013

Abstract

Dabigatran is an oral, direct, and competitive inhibitor of thrombin, which is administered to patients with non-valvular atrial fibrillation for prevention of stroke at a dose of 110 mg twice daily or 150 mg twice daily. Anticoagulation by dabigatran is "hybrid anticoagulation", consisting of action of both dabigatran and physiological coagulation inhibitors because warfarin inhibits production of protein C and protein S but dabigatran does not. Management of dabigatran is easier than that of warfarin because food restriction is unnecessary, drug interaction is small, and absorption time is short and serum concentration corresponds to the anticoagulatory effect in dabigatran treatment. The RE-LY trial confirmed effectiveness and safety of both doses of dabigatran for prevention of stroke and both doses of dabigatran had much lower risks of intracranial bleeding compared with warfarin. Compliance to guidance of dabigatran treatment is essential for avoidance of severe hemorrhagic complications.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeEnglish AbstractJournal ArticleReview
Indexed MeSH termsAdministration, OralAntithrombinsAtrial FibrillationBenzimidazolesDabigatranHemorrhageHumansWarfarinbeta-Alanine

Summary

Dabigatran is an oral direct thrombin inhibitor used at 110 or 150 mg twice daily to prevent stroke in non-valvular atrial fibrillation; per the RE-LY trial, both doses reduced intracranial bleeding compared with warfarin while remaining easier to manage.

Context

This review describes dabigatran, an oral, direct, and competitive thrombin inhibitor used for stroke prevention in non-valvular atrial fibrillation at doses of 110 or 150 mg twice daily. The RE-LY trial confirmed effectiveness and safety of both doses, with lower intracranial bleeding risk compared with warfarin. Dabigatran's management is described as easier than warfarin due to fewer food restrictions, smaller drug interactions, and shorter absorption time. The article shares the general pharmacological theme of direct thrombin inhibition, but the abstract does not mention leeches, hirudotherapy, hirudin, or any leech-derived compound.

Citation

Reference (Vancouver style)

Yasaka M. [Direct oral thrombin inhibitor, "dabigatran"]. Nihon Rinsho. 2013;71(1):113-118. PMID: 23631181

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 28, 2026 · Site last updated: November 1, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.